Charlie's Holdings, Inc.

What they do

Charlie's develops and sells a family of proprietary e-liquids and compact disposable vaping devices, positioned as alternatives to combustible cigarettes for adult smokers. Its portfolio covers three areas: alternative alkaloid (non-nicotine) vapor products, electronic nicotine delivery devices, and premium non-combustible e-liquids. The company is investing in age-gating and access-control technology, including an AI-powered blockchain-based age-gating system licensed from IKE Tech LLC in December, intended to support its FDA Premarket Tobacco Applications (PMTAs).

Revenue drivers

• Alternative alkaloid (non-nicotine) vapor products — The company markets Metatine, a synthetically derived non-nicotine nicotine salt analogue, in vapor devices; the 10-K presents this as one of two broad target product categories alongside non-combustible nicotine products.
• Electronic nicotine delivery devices (ENDS) — Charlie's sells disposable vaping devices and related nicotine vapor products; the 10-K links the company's PMTAs for both flavored and plain tobacco nicotine vapor products to its age-gating technology efforts.
• Premium non-combustible e-liquids — Charlie's formulates and distributes a proprietary family of e-liquids, the product line on which the company built its brand; the excerpts do not break out revenue by product line.
• Licensed age-gating technology — The December definitive licensing agreement with IKE Tech LLC covers commercialization of an AI-powered blockchain-based age-gating system for U.S. vapor products; no revenue contribution from this license is disclosed in the excerpts.

Recent performance

Annual revenue was $20.9 million in 2025, up from $7.8 million in 2024, after declining from $26.4 million in 2022 and $16.3 million in 2023. Net income was $4.5 million in 2025 versus a $4.2 million loss in 2024; diluted EPS was $0.02 in 2025. Despite the profitable year, cash used in operating activities from continuing operations was approximately $6.3 million in 2025 and $2.0 million in 2024. Quarterly revenue fell from $10.5 million in the quarter ended December 31, 2025 to $4.8 million in the quarter ended March 31, 2026 and $3.8 million in the quarter ended June 30, 2026. At June 30, 2026, total assets were $12.8 million, total liabilities $9.7 million, and shareholder equity $3.1 million.

Strategy

Management's stated objective is to become a sales leader in two broad categories: non-combustible nicotine-related products and alternative alkaloid (non-nicotine) vapor products. The primary strategic focus is developing intellectual property related to product access and compliance, particularly advanced age-gating and access-control technologies intended to prevent youth access while preserving availability to adult smokers. The December licensing agreement with IKE Tech LLC to commercialize an AI-powered blockchain-based age-gating system supports the company's PMTAs for flavored and plain tobacco nicotine vapor products. Charlie's states it could become the first company to demonstrate to the FDA that flavored ENDS products are appropriate for the protection of public health. The company frames such a regulatory achievement as potentially transformational for both Charlie's and the vapor products industry.

Risks

• Uncertain cash flow and profitability — The company cautions there is no guarantee it will grow revenue or achieve positive cash flow, and it used approximately $6.3 million in operating cash from continuing operations in 2025.
• Product adoption and retention — The 10-K states that if new or enhanced products fail to engage customers, or if monetization efforts are unsuccessful, the company may fail to attract or retain customers or generate sufficient revenue to justify its investments.
• Regulatory dependence on FDA PMTAs — The stated strategy and the value of the IKE age-gating license depend on demonstrating to the FDA that flavored ENDS products are appropriate for the protection of public health, an outcome the company describes only as a possibility.
• Key personnel loss — The risk factors identify the loss of one or more key personnel as a risk to the business, though the provided excerpt is truncated before explaining the consequences.

Outlook

The filings frame the IKE Tech age-gating license as the centerpiece of the forward plan, describing the possibility of becoming the first company to demonstrate to the FDA that flavored ENDS products are appropriate for the protection of public health. Management states that such a regulatory achievement could prove transformational for Charlie's and the wider vapor products industry. No specific revenue, earnings or cash flow guidance is provided in the excerpted material. The 10-K also states there is no guarantee the company will grow revenue or achieve positive cash flow.